Is 2XD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2XD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2XD (€6.95) is trading above our estimate of fair value (€0.49)
Significantly Below Fair Value: 2XD is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2XD?
Key metric: As 2XD is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
The above table shows the Price to Book ratio for 2XD. This is calculated by dividing 2XD's market cap by their current
book value.
What is 2XD's PB Ratio?
PB Ratio
2.8x
Book
US$669.79m
Market Cap
US$1.92b
2XD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Book vs Industry: 2XD is expensive based on its Price-To-Book Ratio (2.8x) compared to the European Oil and Gas industry average (0.9x).
Price to Book Ratio vs Fair Ratio
What is 2XD's PB Ratio
compared to its
Fair PB Ratio?
This is the expected PB Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
2XD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio
2.8x
Fair PB Ratio
n/a
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2XD's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 2XD forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
€6.95
€10.07
+44.8%
15.9%
€12.27
€8.50
n/a
3
Nov ’25
€5.18
€9.73
+87.9%
15.9%
€11.86
€8.21
n/a
3
Oct ’25
€4.02
€9.73
+142.1%
15.9%
€11.86
€8.21
n/a
3
Sep ’25
€3.97
€9.73
+145.4%
15.9%
€11.86
€8.21
n/a
3
Aug ’25
€7.29
€9.87
+35.3%
15.9%
€12.03
€8.33
n/a
3
Jul ’25
€7.17
€8.72
+21.6%
5.1%
€9.34
€8.41
n/a
3
Jun ’25
€5.86
€8.32
+42.0%
9.1%
€9.24
€7.39
n/a
3
May ’25
€6.09
€7.96
+30.7%
13.2%
€9.37
€6.56
n/a
4
Apr ’25
€4.92
€7.81
+59.0%
13.2%
€9.19
€6.44
n/a
4
Mar ’25
€4.17
€7.81
+87.4%
13.2%
€9.19
€6.44
n/a
4
Feb ’25
€4.63
€7.81
+68.8%
13.2%
€9.19
€6.44
n/a
4
Jan ’25
€4.40
€7.81
+77.6%
13.2%
€9.19
€6.44
n/a
4
Dec ’24
€4.50
€7.81
+73.8%
13.2%
€9.19
€6.44
n/a
4
Nov ’24
€4.10
€8.04
+96.3%
13.2%
€9.46
€6.62
€5.18
4
Oct ’24
€4.85
€8.05
+65.9%
13.2%
€9.47
€6.63
€4.02
4
Sep ’24
€5.51
€7.58
+37.5%
17.9%
€9.19
€5.51
€3.97
4
Aug ’24
€4.98
€7.90
+58.9%
25.9%
€10.69
€5.34
€7.29
4
Jul ’24
€7.48
€7.50
+0.3%
37.0%
€11.08
€4.16
€7.17
4
Jun ’24
€5.10
€8.14
+59.6%
35.9%
€11.06
€4.15
€5.86
3
May ’24
€5.28
€8.02
+51.8%
35.9%
€10.89
€4.08
€6.09
3
Apr ’24
€4.29
€8.18
+91.0%
35.9%
€11.12
€4.17
€4.92
3
Mar ’24
€6.57
€9.05
+37.7%
33.9%
€12.63
€5.15
€4.17
3
Feb ’24
€5.42
€8.45
+56.0%
37.1%
€13.03
€5.31
€4.63
4
Jan ’24
€4.47
€8.45
+89.0%
37.1%
€13.03
€5.31
€4.40
4
Dec ’23
€5.10
€8.45
+65.8%
37.1%
€13.03
€5.31
€4.50
4
Nov ’23
€6.95
€8.80
+26.6%
35.3%
€13.39
€5.95
€4.10
4
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.